Maze Therapeutics
PublicMaze Therapeutics is now publicly traded
The data on this page reflects Maze Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Jan 30, 2025
Last Round
Private Placement
Sep 11, 2025
Total Funding Raised
$944.3M
Company Overview
Maze Therapeutics is a biotechnology company that specializes in translating genetic insights into innovative medicines by leveraging large-scale human genetics data, functional genomics, and diverse drug discovery methods to identify modifier genes and enhance target biology understanding for novel therapy development.
Sector
Biotech
AI Layer
Application
Keywords
Maze Therapeutics Comparables
Compare Maze Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| River 3 Renal Corp. | 62% | |
| AcuraStem | 61% | |
| Mandeville Therapeutics | 59% |
Maze Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Sep 11, 2025 | ||||
| IPO | Jan 30, 2025 | ||||
| Series D | Dec 3, 2024 | ||||
| Series C | Jan 10, 2022 | ||||
| Series B | Feb 1, 2021 | ||||
VC Round | Oct 23, 2019 |
Maze Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series D, Series B, Series C |
| Janus Henderson Group | Series D, Private Placement |
| TCG Crossover | Private Placement |
| GV | Series D, Series B, Series A |
| Guggenheim Securities | IPO |
| Deep Track Capital | Private Placement, Series D |
| Hill City Capital | Series C, VC Round |
Maze Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access